Search Results - "VERSCHRAEGEN, C. F."

Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer by Verschraegen, C.F., Czok, S., Muller, C.Y., Boyd, L., Lee, S.J., Rutledge, T., Blank, S., Pothuri, B., Eberhardt, S., Muggia, F.

“…Suppression of neoangiogenesis and pegylated liposomal doxorubicin (PLD) each contribute to the management of platinum-resistant/refractory ovarian cancer. The…”
Get full text

Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen by Verschraegen, C.F., Arias-Pulido, H., Lee, S.-J., Movva, S., Cerilli, L.A., Eberhardt, S., Schmit, B., Quinn, R., Muller, C.Y., Rabinowitz, I., Purdy, M., Snyder, D., Bocklage, T.

“…To assess the response of patients with soft tissue sarcoma (STS) to the combination of docetaxel, bevacizumab, and gemcitabine. Vascular endothelial growth…”
Get full text

Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix by Verschraegen, C F, Levy, T, Kudelka, A P, Llerena, E, Ende, K, Freedman, R S, Edwards, C L, Hord, M, Steger, M, Kaplan, A L, Kieback, D, Fishman, A, Kavanagh, J J

“…A phase II study was performed to evaluate the antitumor activity and toxicity of irinotecan (CPT-11), a water-soluble derivative of camptothecin, in patients…”
Get more information

Recombinant human thrombopoietin attenuates carboplatin-induced severe Thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer by VADHAN-RAJ, S, VERSCHRAEGEN, C. F, KAVANAGH, J. J, BUESO-RAMOS, C, BROXMEYER, H. E, KUDELKA, A. P, FREEDMAN, R. S, EDWARDS, C. L, GERSHENSON, D, JONES, D, ASHBY, M

“…Thrombocytopenia is a significant problem in the treatment of cancer. To assess the clinical safety of therapy with recombinant human thrombopoietin (rhTPO)…”
Get full text

A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix by KUDELKA, A. P, LEVY, T, JAECKLE, K. A, LOYER, E, STEGER, M, MANTE, R, MAVLIGIT, G, KILLIAN, A, TANG, R. A, GUTTERMAN, J. U, KAVANAGH, J. J, VERSCHRAEGEN, C. F, EDWARDS, C. L, PIAMSOMBOON, S, TERMRUNGRUANGLERT, W, FREEDMAN, R. S, KAPLAN, A. L, KIEBACK, D. G, MEYERS, C. A

“…A Phase I study of the novel angiogenesis inhibitor TNP-470 was performed. Patients with inoperable recurring or metastatic squamous cell cancer of the cervix…”
Get full text

Complete Remission of Metastatic Cervical Cancer with the Angiogenesis Inhibitor TNP-470 by Kudelka, Andrzej P, Verschraegen, Claire F, Loyer, Evelyn

“…To the Editor: TNP-470 is a new inhibitor of angiogenesis that has shown potent antitumor activity in preclinical studies. 1 – 4 We performed a phase 1 study…”
Get full text

Docetaxel for Patients With Paclitaxel-Resistant Müllerian Carcinoma by Verschraegen, C F, Sittisomwong, T, Kudelka, A P, Guedes, E d, Steger, M, Nelson-Taylor, T, Vincent, M, Rogers, R, Atkinson, E N, Kavanagh, J J

“…To determine the efficacy and toxicity of docetaxel in patients with müllerian carcinoma resistant to paclitaxel. Thirty-two patients with epithelial ovarian…”
Get full text

Increased expression of fascin, motility associated protein, in cell cultures derived from ovarian cancer and in borderline and carcinomatous ovarian tumors by Hu, W, McCrea, P D, Deavers, M, Kavanagh, J J, Kudelka, A P, Verschraegen, C F

“…Fascin bundles actin microfilaments within dynamic cellular structures such as microspikes, stress fibers and membrane ruffles. Fascin overexpression induces…”
Get full text

Growth inhibitory effects of aromatic fatty acids on ovarian tumor cell lines by MELICHAR, B, FERRANDINA, G, VERSCHRAEGEN, C. F, LOERCHER, A, ABBRUZZESE, J. L, FREEDMAN, R. S

“…Epithelial ovarian cancer is a major cause of cancer-related mortality in women, making the search for new treatment modalities essential. Sodium phenylacetate…”
Get full text

Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato(trans-R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles by VERSCHRAEGEN, C. F, KUMAGAI, S, DAVIDSON, R, FEIG, B, MANSFIELD, P, LEE, S. J, MACLEAN, D. S, HU, W, KHOKHAR, A. R, SIDDIK, Z. H

“…To perform a phase I study of intraperitoneal cis-bis-neodecanoato ( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar vesicles…”
Get full text

Clinicopathologic analysis of mullerian adenosarcoma: the M.D. Anderson Cancer Center experience by Verschraegen, C F, Vasuratna, A, Edwards, C, Freedman, R, Kudelka, A P, Tornos, C, Kavanagh, J J

“…The records of 41 patients diagnosed with adenosarcoma of the female genital tract between 1982 and 1996 were reviewed. The median age at diagnosis is 51 years…”
Get more information

Paraneoplastic syndromes of gynecologic neoplasms by Ashour, A A, Verschraegen, C F, Kudelka, A P, Kavanagh, J J

“…The purpose of this review is to define and describe the paraneoplastic syndromes associated with gynecologic neoplasms. A comprehensive search of MEDLINE from…”
Get more information

Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum by KAVANAGH, J. J, KUDELKA, A. P, EDWARDS, C. L, FREEDMAN, R. S, VERSCHRAEGEN, C. F, DE LEON, C. G, TRESUKOSOL, D, HORD, D, FINNEGAN, M. B, KIM, E. E, VARMA, D, FORMAN, A, COHEN, P

“…We analyzed the efficacy and toxicity of docetaxel in patients with ovarian cancer who failed previous chemotherapy with platinum. Fifty-five patients with…”
Get full text

Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumour specimens, peritoneal exudate cells containing tumour, tumour‐infiltrating lymphocyte (TIL)‐derived T cell lines and established tumour cell lines by NASH, M. A, LENZI, R, EDWARDS, C. L, KAVANAGH, J. J, KUDELKA, A. P, VERSCHRAEGEN, C. F, PLATSOUCAS, C. D, FREEDMAN, R. S

“…T cell lines derived in low concentrations of recombinant IL‐2 (rIL‐2) from TIL of patients with epithelial ovarian carcinoma (EOC) often exhibit specific…”
Get full text

Feasibility, Phase I, and Pharmacological Study of Aerosolized Liposomal 9-Nitro-20(S)-Camptothecin in Patients with Advanced Malignancies in the Lungs by VERSCHRAEGEN, C. F., GILBERT, B. E., HUARINGA, A. J., NEWMAN, R., HARRIS, N., LEYVA, F. J., KEUS, L., CAMPBELL, K., NELSON-TAYLOR, T., KNIGHT, V.

Get full text

Absence of epidermal growth factor receptor mutations in cervical cancer by Arias-Pulido, H, Joste, N, Chavez, A, Muller, C Y, Dai, D, Smith, H O, Verschraegen, C F

“…Epidermal growth factor receptor (EGFR) is overexpressed in the majority of cervical cancers (CCs). Somatic mutations of EGFR have been associated with…”
Get more information

Alternative Administration of Camptothecin Analogues by VERSCHRAEGEN, C. F., JAECKLE, K., GIOVANELLA, B., KNIGHT, V., GILBERT, B. E.

“…: The binding of camptothecin (CPT) to the DNA‐topoisomerase complex is reversible, but it needs to be maintained for maximal inhibitory activity. It is also…”
Get full text

Effects of interleukin-1α on ovarian carcinoma in patients with recurrent disease by Verschraegen, C.F., Kudelka, A.P., Termrungruanglert, W., de Leon, C.G., Edwards, C.L., Freedman, R.S., Kavanagh, J.J., Vadhan-Raj, S.

“…The aim of this study was to evaluate the safety and the biological effects of interleukin (IL-1α) in patients with recurrent ovarian carcinoma treated with…”
Get full text

Growth inhibitory effects of sodium phenylacetate (NSC 3039) on ovarian carcinoma cells in vitro by FERRANDINA, G, MELICHAR, B, LOERCHER, A, VERSCHRAEGEN, C. F, KUDELKA, A. P, EDWARDS, C. L, SCAMBIA, G, KAVANAGH, J. J, ABBRUZZESE, J. L, FREEDMAN, R. S

“…The aim of this study was to determine the antiproliferative activity of sodium phenylacetate (NaPa) against ovarian carcinoma cell lines. NaPa induced a…”
Get full text

Vulvar melanoma at the M. D. Anderson Cancer Center: 25 years later by Verschraegen, C F, Benjapibal, M, Supakarapongkul, W, Levy, L B, Ross, M, Atkinson, E N, Bodurka-Bevers, D, Kavanagh, J J, Kudelka, A P, Legha, S S

“…The purpose of this study was to review the clinical course of patients diagnosed with vulvar melanoma. Charts of patients diagnosed between 1970 and 1997 were…”
Get more information